Preparation	O
and	O
evaluation	B:C0220825
of	O
biopolymeric	O
nanoparticles	O
as	O
drug	O
delivery	I:C0085104
system	I:C0085104
in	O
effective	O
treatment	O
of	O
rheumatoid	O
arthritis	I:C0003873
.	O

Preparation	O
and	O
evaluation	O
of	O
biopolymeric	B:C0005554
nanoparticles	O
as	O
drug	O
delivery	I:C0085104
system	I:C0085104
in	O
effective	O
treatment	O
of	O
rheumatoid	O
arthritis	I:C0003873
.	O

Preparation	O
and	O
evaluation	O
of	O
biopolymeric	O
nanoparticles	O
as	O
drug	B:C0085104
delivery	I:C0085104
system	I:C0085104
in	O
effective	O
treatment	O
of	O
rheumatoid	O
arthritis	I:C0003873
.	O

Preparation	O
and	O
evaluation	O
of	O
biopolymeric	O
nanoparticles	O
as	O
drug	O
delivery	I:C0085104
system	I:C0085104
in	O
effective	O
treatment	B:C0087111
of	O
rheumatoid	O
arthritis	I:C0003873
.	O

Preparation	O
and	O
evaluation	O
of	O
biopolymeric	O
nanoparticles	O
as	O
drug	O
delivery	I:C0085104
system	I:C0085104
in	O
effective	O
treatment	O
of	O
rheumatoid	B:C0003873
arthritis	I:C0003873
.	O

The	O
study	O
purposes	O
to	O
evaluate	B:C0220825
nanocrystalline	O
biopolymeric	O
nanoparticles	O
encapsulating	O
methotrexate	O
and	O
dexamethasone	O
with	O
high	O
biocompatibility	O
,	O
enhanced	O
therapeutic	O
efficacy	O
and	O
reduced	O
toxicity	O
.	O

The	O
study	O
purposes	O
to	O
evaluate	O
nanocrystalline	O
biopolymeric	B:C0005554
nanoparticles	O
encapsulating	O
methotrexate	O
and	O
dexamethasone	O
with	O
high	O
biocompatibility	O
,	O
enhanced	O
therapeutic	O
efficacy	O
and	O
reduced	O
toxicity	O
.	O

The	O
study	O
purposes	O
to	O
evaluate	O
nanocrystalline	O
biopolymeric	O
nanoparticles	O
encapsulating	O
methotrexate	B:C0025677
and	O
dexamethasone	O
with	O
high	O
biocompatibility	O
,	O
enhanced	O
therapeutic	O
efficacy	O
and	O
reduced	O
toxicity	O
.	O

The	O
study	O
purposes	O
to	O
evaluate	O
nanocrystalline	O
biopolymeric	O
nanoparticles	O
encapsulating	O
methotrexate	O
and	O
dexamethasone	B:C0011777
with	O
high	O
biocompatibility	O
,	O
enhanced	O
therapeutic	O
efficacy	O
and	O
reduced	O
toxicity	O
.	O

Chitosan	B:C0162969
nanoparticles	O
were	O
prepared	O
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	O
(	O
Methotrexate	O
)	O
and	O
Dexamethasone	O
(	O
Dexamethasone	O
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	O
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	O
and	O
RAW264.7	O
cells	I:C4042840
,	O
ex	O
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

Chitosan	O
nanoparticles	O
were	O
prepared	B:C4082130
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	O
(	O
Methotrexate	O
)	O
and	O
Dexamethasone	O
(	O
Dexamethasone	O
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	O
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	O
and	O
RAW264.7	O
cells	I:C4042840
,	O
ex	O
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

Chitosan	O
nanoparticles	O
were	O
prepared	O
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	B:C0025677
(	O
Methotrexate	O
)	O
and	O
Dexamethasone	O
(	O
Dexamethasone	O
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	O
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	O
and	O
RAW264.7	O
cells	I:C4042840
,	O
ex	O
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

Chitosan	O
nanoparticles	O
were	O
prepared	O
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	O
(	O
Methotrexate	B:C0025677
)	O
and	O
Dexamethasone	O
(	O
Dexamethasone	O
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	O
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	O
and	O
RAW264.7	O
cells	I:C4042840
,	O
ex	O
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

Chitosan	O
nanoparticles	O
were	O
prepared	O
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	O
(	O
Methotrexate	O
)	O
and	O
Dexamethasone	B:C0011777
(	O
Dexamethasone	O
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	O
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	O
and	O
RAW264.7	O
cells	I:C4042840
,	O
ex	O
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

Chitosan	O
nanoparticles	O
were	O
prepared	O
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	O
(	O
Methotrexate	O
)	O
and	O
Dexamethasone	O
(	O
Dexamethasone	B:C0011777
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	O
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	O
and	O
RAW264.7	O
cells	I:C4042840
,	O
ex	O
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

Chitosan	O
nanoparticles	O
were	O
prepared	O
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	O
(	O
Methotrexate	O
)	O
and	O
Dexamethasone	O
(	O
Dexamethasone	O
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	B:C0373483
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	O
and	O
RAW264.7	O
cells	I:C4042840
,	O
ex	O
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

Chitosan	O
nanoparticles	O
were	O
prepared	O
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	O
(	O
Methotrexate	O
)	O
and	O
Dexamethasone	O
(	O
Dexamethasone	O
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	O
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	B:C2936239
and	O
RAW264.7	O
cells	I:C4042840
,	O
ex	O
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

Chitosan	O
nanoparticles	O
were	O
prepared	O
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	O
(	O
Methotrexate	O
)	O
and	O
Dexamethasone	O
(	O
Dexamethasone	O
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	O
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	O
and	O
RAW264.7	B:C4042840
cells	I:C4042840
,	O
ex	O
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

Chitosan	O
nanoparticles	O
were	O
prepared	O
by	O
ionic	O
gelation	O
,	O
and	O
Methotrexate	O
(	O
Methotrexate	O
)	O
and	O
Dexamethasone	O
(	O
Dexamethasone	O
)	O
were	O
loaded	O
during	O
the	O
preparation	O
and	O
screened	O
for	O
their	O
in	O
vitro	O
efficacy	O
in	O
HEK	O
and	O
RAW264.7	O
cells	I:C4042840
,	O
ex	B:C0242481
vivo	I:C0242481
and	O
in	O
vivo	O
efficacy	O
.	O

FTIR	B:C0206055
confirmed	O
the	O
involvement	O
of	O
phosphoric	O
group	O
of	O
sTPP	O
with	O
amine	O
groups	I:C1879694
of	O
chitosan	O
and	O
also	O
role	O
of	O
hydrogen	O
bonding	O
involved	O
in	O
the	O
preparation	O
of	O
MTXCHNP	O
and	O
DEXCHNP	O
.	O

FTIR	O
confirmed	O
the	O
involvement	O
of	O
phosphoric	O
group	O
of	O
sTPP	B:C0301008
with	O
amine	O
groups	I:C1879694
of	O
chitosan	O
and	O
also	O
role	O
of	O
hydrogen	O
bonding	O
involved	O
in	O
the	O
preparation	O
of	O
MTXCHNP	O
and	O
DEXCHNP	O
.	O

FTIR	O
confirmed	O
the	O
involvement	O
of	O
phosphoric	O
group	O
of	O
sTPP	O
with	O
amine	B:C1879694
groups	I:C1879694
of	O
chitosan	O
and	O
also	O
role	O
of	O
hydrogen	O
bonding	O
involved	O
in	O
the	O
preparation	O
of	O
MTXCHNP	O
and	O
DEXCHNP	O
.	O

FTIR	O
confirmed	O
the	O
involvement	O
of	O
phosphoric	O
group	O
of	O
sTPP	O
with	O
amine	O
groups	I:C1879694
of	O
chitosan	B:C0162969
and	O
also	O
role	O
of	O
hydrogen	O
bonding	O
involved	O
in	O
the	O
preparation	O
of	O
MTXCHNP	O
and	O
DEXCHNP	O
.	O

Controlled	O
release	O
patterns	O
coupled	O
with	O
diffusion	O
of	O
drug	B:C1254351
were	O
observed	O
in	O
two	O
different	O
buffers	O
(	O
PBS	O
)	O
at	O
pH	O
7.4	O
and	O
pH	O
5.8	O
.	O

Controlled	O
release	O
patterns	O
coupled	O
with	O
diffusion	O
of	O
drug	O
were	O
observed	O
in	O
two	O
different	O
buffers	B:C0006353
(	O
PBS	O
)	O
at	O
pH	O
7.4	O
and	O
pH	O
5.8	O
.	O

Controlled	O
release	O
patterns	O
coupled	O
with	O
diffusion	O
of	O
drug	O
were	O
observed	O
in	O
two	O
different	O
buffers	O
(	O
PBS	B:C0991865
)	O
at	O
pH	O
7.4	O
and	O
pH	O
5.8	O
.	O

The	O
IC50	O
for	O
MTXCHNP	O
for	O
HEK	B:C2936239
was	O
26.1	O
μg/ml	O
and	O
7.7	O
μg/	O
ml	O
for	O
RAW	O
264.7	I:C4042840
cells	I:C4042840
.	O

The	O
IC50	O
for	O
MTXCHNP	O
for	O
HEK	O
was	O
26.1	O
μg/ml	O
and	O
7.7	O
μg/	O
ml	O
for	O
RAW	B:C4042840
264.7	I:C4042840
cells	I:C4042840
.	O

In	O
DEXCHNP	O
,	O
the	O
IC50	O
was	O
20.12	O
μg/	O
ml	O
for	O
HEK	B:C2936239
and	O
7.37	O
μg/ml	O
for	O
RAW264.7	O
cells	I:C4042840
.	O

In	O
DEXCHNP	O
,	O
the	O
IC50	O
was	O
20.12	O
μg/	O
ml	O
for	O
HEK	O
and	O
7.37	O
μg/ml	O
for	O
RAW264.7	B:C4042840
cells	I:C4042840
.	O

Enhanced	O
uptake	O
of	O
FITC	O
-	O
CHNP	O
by	O
RAW	B:C0007634
cells	I:C0007634
indicated	O
internalization	O
of	O
nanoparticles	O
by	O
phagocytosis	O
.	O

Enhanced	O
uptake	O
of	O
FITC	O
-	O
CHNP	O
by	O
RAW	O
cells	I:C0007634
indicated	O
internalization	O
of	O
nanoparticles	O
by	O
phagocytosis	B:C0031308
.	O

The	O
enhanced	O
release	O
of	O
drug	B:C1254351
at	O
lower	O
pH	O
justified	O
increased	O
cytotoxicity	O
.	O

The	O
enhanced	O
release	O
of	O
drug	O
at	O
lower	O
pH	O
justified	O
increased	O
cytotoxicity	B:C0596402
.	O

Negligible	O
ex-vivo	B:C0242481
hemolysis	O
indicated	O
the	O
higher	O
biocompatibility	O
of	O
the	O
nanoparticles	O
.	O

Negligible	O
ex-vivo	O
hemolysis	B:C2945560
indicated	O
the	O
higher	O
biocompatibility	O
of	O
the	O
nanoparticles	O
.	O

(	B:C0303611
99	I:C0303611
m	I:C0303611
)	I:C0303611
Tc	I:C0303611
-	O
CHNP	O
exhibited	O
maximum	O
absorption	O
in	O
blood	O
circulation	I:C0005775
in	O
3	O
h	O
,	O
followed	O
by	O
hepatic	O
metabolism	I:C1373178
and	O
renal	O
clearance	I:C0232813
.	O

(	O
99	I:C0303611
m	I:C0303611
)	I:C0303611
Tc	I:C0303611
-	O
CHNP	O
exhibited	O
maximum	O
absorption	O
in	O
blood	B:C0005775
circulation	I:C0005775
in	O
3	O
h	O
,	O
followed	O
by	O
hepatic	O
metabolism	I:C1373178
and	O
renal	O
clearance	I:C0232813
.	O

(	O
99	I:C0303611
m	I:C0303611
)	I:C0303611
Tc	I:C0303611
-	O
CHNP	O
exhibited	O
maximum	O
absorption	O
in	O
blood	O
circulation	I:C0005775
in	O
3	O
h	O
,	O
followed	O
by	O
hepatic	B:C1373178
metabolism	I:C1373178
and	O
renal	O
clearance	I:C0232813
.	O

(	O
99	I:C0303611
m	I:C0303611
)	I:C0303611
Tc	I:C0303611
-	O
CHNP	O
exhibited	O
maximum	O
absorption	O
in	O
blood	O
circulation	I:C0005775
in	O
3	O
h	O
,	O
followed	O
by	O
hepatic	O
metabolism	I:C1373178
and	O
renal	B:C0232813
clearance	I:C0232813
.	O

Higher	O
in	O
-vivo	O
anti-arthritic	B:C0243095
activity	I:C0243095
and	O
antioxidant	O
activity	I:C1148564
was	O
observed	O
post	O
-	I:C0021493
intraperitoneal	I:C0021493
(	I:C0021493
i.p.	I:C0021493
)	I:C0021493
injections	I:C0021493
by	O
both	O
MTXCHNP	O
and	O
DEXCHNP	O
when	O
compared	O
to	O
Methotrexate	O
(	O
0.75	O
mg	O
/	O
Kg	O
by	O
i.p.	O
route	O
)	O
and	O
Dexamethasone	O
(	O
0.2	O
mg	O
/	O
Kg/	O
i.p.	O
/	O
daily	O
)	O
per	O
se	O
.	O

Higher	O
in	O
-vivo	O
anti-arthritic	O
activity	I:C0243095
and	O
antioxidant	B:C1148564
activity	I:C1148564
was	O
observed	O
post	O
-	I:C0021493
intraperitoneal	I:C0021493
(	I:C0021493
i.p.	I:C0021493
)	I:C0021493
injections	I:C0021493
by	O
both	O
MTXCHNP	O
and	O
DEXCHNP	O
when	O
compared	O
to	O
Methotrexate	O
(	O
0.75	O
mg	O
/	O
Kg	O
by	O
i.p.	O
route	O
)	O
and	O
Dexamethasone	O
(	O
0.2	O
mg	O
/	O
Kg/	O
i.p.	O
/	O
daily	O
)	O
per	O
se	O
.	O

Higher	O
in	O
-vivo	O
anti-arthritic	O
activity	I:C0243095
and	O
antioxidant	O
activity	I:C1148564
was	O
observed	O
post	B:C0021493
-	I:C0021493
intraperitoneal	I:C0021493
(	I:C0021493
i.p.	I:C0021493
)	I:C0021493
injections	I:C0021493
by	O
both	O
MTXCHNP	O
and	O
DEXCHNP	O
when	O
compared	O
to	O
Methotrexate	O
(	O
0.75	O
mg	O
/	O
Kg	O
by	O
i.p.	O
route	O
)	O
and	O
Dexamethasone	O
(	O
0.2	O
mg	O
/	O
Kg/	O
i.p.	O
/	O
daily	O
)	O
per	O
se	O
.	O

Higher	O
in	O
-vivo	O
anti-arthritic	O
activity	I:C0243095
and	O
antioxidant	O
activity	I:C1148564
was	O
observed	O
post	O
-	I:C0021493
intraperitoneal	I:C0021493
(	I:C0021493
i.p.	I:C0021493
)	I:C0021493
injections	I:C0021493
by	O
both	O
MTXCHNP	O
and	O
DEXCHNP	O
when	O
compared	O
to	O
Methotrexate	B:C0025677
(	O
0.75	O
mg	O
/	O
Kg	O
by	O
i.p.	O
route	O
)	O
and	O
Dexamethasone	O
(	O
0.2	O
mg	O
/	O
Kg/	O
i.p.	O
/	O
daily	O
)	O
per	O
se	O
.	O

Higher	O
in	O
-vivo	O
anti-arthritic	O
activity	I:C0243095
and	O
antioxidant	O
activity	I:C1148564
was	O
observed	O
post	O
-	I:C0021493
intraperitoneal	I:C0021493
(	I:C0021493
i.p.	I:C0021493
)	I:C0021493
injections	I:C0021493
by	O
both	O
MTXCHNP	O
and	O
DEXCHNP	O
when	O
compared	O
to	O
Methotrexate	O
(	O
0.75	O
mg	O
/	O
Kg	O
by	O
i.p.	O
route	O
)	O
and	O
Dexamethasone	B:C0011777
(	O
0.2	O
mg	O
/	O
Kg/	O
i.p.	O
/	O
daily	O
)	O
per	O
se	O
.	O

The	O
nanocrystalline	O
biopolymeric	B:C0005554
nanoparticles	O
were	O
stable	O
,	O
biocompatible	O
and	O
have	O
potential	O
to	O
be	O
administered	O
through	O
i.p.	O
route	O
with	O
minimal	O
toxicity	O
and	O
high	O
efficacy	O
.	O

